BNOS 2022 | The potential role of BRAFV600 inhibitors in glioblastoma

Zak Thornton, University of Bristol, Bristol, UK, discusses the results of a systematic review that assessed BRAFV600 inhibitors in treating glioblastoma. The review included patients with varying types of brain tumors, including pediatric patients with polymorphous low-grade neuroepithelial tumor of the young (PLNTY). A majority of the cohort who received BRAFV600 inhibitors received dabrafenib or vemurafenib and patients who additionally received MEK inhibitors had better outcomes than patients who solely received BRAFV600 inhibitors. Tumor sequencing in patients with brain tumors consequently will be beneficial to those eligible for targeted therapies. This interview took place at the British Neuro-Oncology Society (BNOS) Annual Meeting 2022.